PMDA drug package insert
エジュラント錠25mg
PMDA Prescription drug · ヤンセンファーマ株式会社 · package insert Aug 25, 2026
Key facts
| Brand names | エジュラント錠25mg |
|---|---|
| Nonproprietary names | リルピビリン塩酸塩 |
| Companies | 製造販売元（輸入）／ヤンセンファーマ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗ウイルス化学療法剤［非ヌクレオシド系逆転写酵素阻害剤（NNRTI）］ |
| Therapeutic category codes | 87625 |
| YJ codes | 6250036F1024 |
| Approval numbers | 22400AMX00687000 |
| Package insert edition | 第8版 |
| Package insert date | Aug 25, 2026 |
| PMDA document key | 800155_6250036F1024_1 |
| PMDA company code | 800155 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: